Cy­to­ki­net­ic­s' lat­est PhI­II study of ome­cam­tiv flops — kick­ing out an­oth­er leg from un­der the mar­ket case it was build­ing

Cy­to­ki­net­ics’ re­lent­less quest to demon­strate that its heart drug ome­cam­tiv has re­al val­ue ran in­to an­oth­er thick­et of bad da­ta Tues­day morn­ing.

The biotech re­port­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER